Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential

Page 9 of 9

1. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Renaissance Technologies’ Stake Value: $312,347,555

Upside Potential as of May 1: 87.12%

Market Capitalization as of May 1: $7.51 Billion

Number of Hedge Fund Holders: 29

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company that develops and markets medicines for serious health disorders related to excess cortisol. Its flagship product, Korlym (mifepristone), is used to treat high blood sugar in patients with Cushing’s syndrome. The company is also developing other drugs targeting cortisol-related conditions.

In Q4 2024, Corcept Therapeutics Incorporated’s (NASDAQ:CORT) annual revenue was $675.0 million, a 40% increase over the fiscal year 2023. The company posted a net income of $141.2 million for the full year, which translates to $1.23 diluted earnings per share compared to $0.94 in the previous year. According to CEO Joseph K. Belanoff, M.D., the solid performance arose from “a record number of new Korlym® prescribers and a record number of patients receiving Korlym in the quarter.”

Korlym aside, Corcept Therapeutics Incorporated (NASDAQ:CORT) is making substantial progress across its clinical development pipeline. The company submitted a New Drug Application (NDA) for relacorilant in hypercortisolism in December 2024. Additionally, the firm will present late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025. On April 3, 2025, Piper Sandler raised its price target to $131.00 from $128.00 while maintaining an Overweight rating on the stock. The firm said it based the decision on the announcement of successful Phase 3 ROSELLA study results in platinum-resistant ovarian cancer.

While we acknowledge the potential of Corcept Therapeutics Incorporated (NASDAQ:CORT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CORT but that trades at less than 5 times its earnings check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9